NASDAQ:UMRXUnum Therapeutics Stock Price, Forecast & News

$0.55

+0.00 (+0.02 %)

(As of 06/4/2020 04:00 PM ET)

Add

Compare

Today's Range

$0.53

Now: $0.55▼

$0.55

50-Day Range

$0.37

MA: $0.46▼

$0.59

52-Week Range

$0.30

Now: $0.55▼

$3.50

Volume127,900 shs

Average Volume424,942 shs

Market Capitalization$17.08 million

P/E RatioN/A

Dividend YieldN/A

Beta1.33

Unum Therapeutics Inc., a biopharmaceutical company, develops and commercializes immunotherapy products for cancer. The company is developing ACTR707 used in combination with rituximab, which is in Phase I clinical trials to treat adult patients with relapsed or refractory CD20+ non-Hodgkin lymphoma (r/r NHL). Its product portfolio also includes ACTR087 used in combination with rituximab that is in Phase I clinical trials to treat adult patients with r/r NHL; ACTR087 used in combination with SEA-BCMA, which is in Phase I clinical trials for treating patients with r/r multiple myeloma; ACTR707 used in combination with trastuzumab that is in Phase I clinical trials for treating HER2+ solid tumor cancers; and BOXR1030, which is in pre-clinical stage, targets glypican-3 that improve T cell functionality in the solid tumor microenvironment. Unum Therapeutics Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.

Beat the Market (BTM) Rank^™

3.2 Analyst's Opinion

Consensus Rating
Unum Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on 2 buy ratings, 3 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $3.50, Unum Therapeutics has a potential upside of 538.7% from its current price of $0.55.
Amount of Analyst Coverage
Unum Therapeutics has only been the subject of 2 research reports in the past 90 days.

2.5 Community Rank

Outperform Votes
Unum Therapeutics has received 167 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Unum Therapeutics has received 168 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Unum Therapeutics has received 50.15% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Unum Therapeutics and other stocks. Vote “Outperform” if you believe UMRX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe UMRX will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Unum Therapeutics does not currently pay a dividend.
Dividend Growth
Unum Therapeutics does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Unum Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 31.50% of the stock of Unum Therapeutics is held by insiders.
Percentage Held by Institutions
Only 29.19% of the stock of Unum Therapeutics is held by institutions.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Unum Therapeutics are expected to decrease in the coming year, from ($0.53) to ($0.59) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Unum Therapeutics is -0.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Unum Therapeutics is -0.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Unum Therapeutics has a P/B Ratio of 0.53. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.27 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:UMRX

Previous Symbol

CUSIPN/A

CIK1622229

Webwww.unumrx.com

Phone617-945-5576

Debt

Debt-to-Equity Ratio0.16

Current Ratio3.37

Quick Ratio3.37

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$22.50 million

Price / Sales0.76

Cash FlowN/A

Price / Cash FlowN/A

Book Value$1.04 per share

Price / Book0.53

Profitability

EPS (Most Recent Fiscal Year)($1.04)

Net Income$-31,830,000.00

Net Margins-99.09%

Return on Equity-83.39%

Return on Assets-48.69%

Miscellaneous

Employees72

Outstanding Shares31,162,000

Market Cap$17.08 million

Next Earnings Date8/10/2020 (Estimated)

OptionableNot Optionable

Receive UMRX News and Ratings via Email

Sign-up to receive the latest news and ratings for UMRX and its competitors with MarketBeat's FREE daily newsletter.

Unum Therapeutics (NASDAQ:UMRX) Frequently Asked Questions

How has Unum Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Unum Therapeutics' stock was trading at $0.3736 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, UMRX stock has increased by 46.7% and is now trading at $0.5480. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Unum Therapeutics?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Unum Therapeutics in the last year. There are currently 3 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Unum Therapeutics.

When is Unum Therapeutics' next earnings date?

Unum Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, August 10th 2020. View our earnings forecast for Unum Therapeutics.

How were Unum Therapeutics' earnings last quarter?

Unum Therapeutics Inc (NASDAQ:UMRX) issued its quarterly earnings results on Monday, May, 11th. The company reported ($0.20) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.30) by $0.10. The business had revenue of $7.03 million for the quarter, compared to the consensus estimate of $3 million. Unum Therapeutics had a negative net margin of 99.09% and a negative return on equity of 83.39%. View Unum Therapeutics' earnings history.

What price target have analysts set for UMRX?

5 analysts have issued 1-year price objectives for Unum Therapeutics' stock. Their forecasts range from $1.00 to $6.00. On average, they anticipate Unum Therapeutics' share price to reach $3.50 in the next twelve months. This suggests a possible upside of 538.7% from the stock's current price. View analysts' price targets for Unum Therapeutics.

What are Wall Street analysts saying about Unum Therapeutics stock?

Here are some recent quotes from research analysts about Unum Therapeutics stock:

1. According to Zacks Investment Research, "Unum Therapeutics Inc. is a biopharmaceutical company. It focused on the development and commercialization of novel immunotherapy products of immune system to cure cancer. The company's program consists of ACTR087 rituximab, ACTR707 RITUXIMAB, ACTR087 SEA-BCMA which are in clinical stage. Unum Therapeutics Inc. is based in Cambridge, United States. " (5/30/2020)
2. HC Wainwright analysts commented, "Our price target of $18/share is based on an equally-weighted composite of: (a) $18.0/share, as a 25x multiple of taxed and diluted $7.63 discounted back to FY19 at 30% (in line with the expected PE multiple and discount rate of an early development-stage biotechnology company); and (b) an NPV of $17.5/share (discounted cash flow analysis using a 18.0% discount rate and 2.0% growth rate, in line with the expected discount and growth parameters of an early development-stage biotechnology company)." (8/13/2019)

Has Unum Therapeutics been receiving favorable news coverage?

Media stories about UMRX stock have been trending somewhat positive recently, according to InfoTrie Sentiment. InfoTrie rates the sentiment of media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Unum Therapeutics earned a media sentiment score of 1.6 on InfoTrie's scale. They also gave news stories about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View the latest news aboutUnum Therapeutics.

Are investors shorting Unum Therapeutics?

Unum Therapeutics saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 362,200 shares, an increase of 14.2% from the April 30th total of 317,300 shares. Based on an average trading volume of 435,800 shares, the short-interest ratio is presently 0.8 days. Approximately 2.5% of the shares of the company are sold short. View Unum Therapeutics' Current Options Chain.

Who are some of Unum Therapeutics' key competitors?

Some companies that are related to Unum Therapeutics include Heat Biologics (HTBX), CannTrust (CNTTF), Trevi Therapeutics (TRVI), VERONA PHARMA P/S (VRNA), Aridis Pharmaceuticals (ARDS), Vaccinex (VCNX), ASLAN PHARMACEU/ADR (ASLN), Aclaris Therapeutics (ACRS), American Brivision (Holding) (ABVC), Acasti Pharma (ACST), Evoke Pharma (EVOK), Eyenovia (EYEN), Zosano Pharma (ZSAN), OncoSec Medical (ONCS) and Vascular Biogenics (VBLT). View all competitors.

What other stocks do shareholders of Unum Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Unum Therapeutics investors own include Amplify Energy (AMPY), Amplify Energy (AMPY), Matinas BioPharma (MTNB), Outlook Therapeutics (OTLK), ADMA Biologics (ADMA), AzurRx BioPharma (AZRX), Miragen Therapeutics (MGEN), Polarityte (PTE), KushCo (KSHB) and Titan Pharmaceuticals (TTNP).

Who are Unum Therapeutics' key executives?

Unum Therapeutics' management team includes the following people:

Dr. Charles Wilson, CEO, Pres & Director (Age 55, Pay $807.42k)
Mr. Matthew S. Osborne, Chief Financial Officer (Age 48, Pay $517.98k)
Dr. Dario Campana, Scientific Founder & Chair of Scientific Advisory Board
Mr. John L. Green C.A., C.P.A., Principal Accounting Officer (Age 40)
Mr. Larry Weiner, VP of Technical Operations

When did Unum Therapeutics IPO?

(UMRX) raised $75 million in an IPO on Thursday, March 29th 2018. The company issued 5,800,000 shares at $12.00-$14.00 per share. Morgan Stanley and Cowen served as the underwriters for the IPO and SunTrust Robinson Humphrey and Wedbush Securities were co-managers.

What is Unum Therapeutics' stock symbol?

Unum Therapeutics trades on the NASDAQ under the ticker symbol "UMRX."

How do I buy shares of Unum Therapeutics?

Shares of UMRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Unum Therapeutics' stock price today?

One share of UMRX stock can currently be purchased for approximately $0.55.

How big of a company is Unum Therapeutics?

Unum Therapeutics has a market capitalization of $17.08 million and generates $22.50 million in revenue each year. The company earns $-31,830,000.00 in net income (profit) each year or ($1.04) on an earnings per share basis. Unum Therapeutics employs 72 workers across the globe.

What is Unum Therapeutics' official website?

The official website for Unum Therapeutics is www.unumrx.com.

How can I contact Unum Therapeutics?

Unum Therapeutics' mailing address is 200 CAMBRIDGE PARK DRIVE SUITE 3100, CAMBRIDGE MA, 02140. The company can be reached via phone at 617-945-5576 or via email at [email protected]

This page was last updated on 6/4/2020 by MarketBeat.com Staff